DMK Pharmaceuticals (DMKPQ) Stock Statistics & Valuation Metrics

DMK Pharmaceuticals has a market cap or net worth of ―. The enterprise value is ―.

DMK Pharmaceuticals has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

DMK Pharmaceuticals’s return on equity (ROE) is 40.69 and return on invested capital (ROIC) is 20463.87%.

The current PE Ratio of DMK Pharmaceuticals is ―. DMK Pharmaceuticals’s PEG ratio is 0.00218.

In the last 12 months, DMK Pharmaceuticals had revenue of 4.76M and earned -26.48M in profits. Earnings per share was -12.37.

In the last 12 months, operating cash flow was -9.38M and capital expenditures -91.49K, giving a free cash flow of -9.47M billion.

DMK Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

DMK Pharmaceuticals upcoming earnings date is Nov 12, 2024, TBA (Confirmed).

DMK Pharmaceuticals as a current ratio of 0.81, with Debt / Equity ratio of -52.64%

In the past 12 months, DMK Pharmaceuticals has paid 2.00K in taxes.

DMK Pharmaceuticals EV to EBITDA ratio is -0.08, with an EV/FCF ratio of -0.07.

DMK Pharmaceuticals has $6.66M in cash and marketable securities with $63.21K in debt, giving a net cash position of $6.60M billion.

Gross margin is -60.93%, with operating margin of -526.88%, and net profit margin of -556.72%.

The average price target for DMK Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―